TrialReader


Quadratus Lumborum Block vs Transversus Abdominis Plane Block for Post-prostatectomy Analgesia

NCT03606889 — Not applicable, Terminated, 12 participants, Jagiellonian University

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT03606889
StatusTerminated - not enough participants
PhaseNot applicable
Study typeInterventional; randomized, parallel, masking: quadruple, treatment
Enrollment12 (Actual)
SponsorJagiellonian University (Other)
ConditionsProstatic Cancer, Pain, Postoperative, Pain, Anesthetics, Local
InterventionsQuadratus Lumborum block, Tranversus Abdominis plane block, Bupivacaine (Diagnostic test, drug)
Datesstart 2018-07-31, primary completion 2021-12-31, completion 2021-12-31, first posted 2018-07-31, last updated 2022-06-06
Locations1 site in Poland

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Prostatic Cancer All trials for Pain, Postoperative All trials of Quadratus Lumborum block All trials of Tranversus Abdominis plane block

-Summary

Recently, the uses of peripheral axial blocks that deliver local anesthetic into the transversus abdominis fascial plane have become popular for operations that involve incision(s) of the abdominal wall. Thus, the Transversus Abdominis plane (TAP) block has been shown to reduce perioperative opioid use in elective abdominal surgery, including open appendicectomy, laparotomy, and laparoscopic cholecystectomy.

Currently, the Quadratus Lumborum block (QL block) is performed as one of the perioperative pain management procedures for all generations (pediatrics, pregnant, and adult) undergoing abdominal surgery. The local anesthetic injected via the approach of the posterior QL block ( QL 2 block ) can more easily extend beyond the TAP to the thoracic paravertebral space or the thoracolumbar plane, the posterior QL block entails a broader sensory-level analgesic and may generate analgesia from T7 to L1. Use of posterior QL block in laparoscopic prostatectomy has not been investigated before and it is the variant that will be discussed in our study.

Expand all sections  ·  Collapse all

+Detailed description

In laparoscopic prostatectomy, overall pain is a conglomerate of three different and clinically separate components: incisional pain (somatic pain), visceral pain (deep intra abdominal pain), and shoulder pain due to peritoneal stretching and diaphragmatic irritation associated with carbon dioxide insufflation. Moreover, it has been hypothesized that intense acute pain after laparoscopic prostatectomy may predict development of chronic pain. Without effective treatment, this ongoing pain may delay recovery, mandate inpatient admission, and thereby increase the cost of such care.

+Arms and interventions

ArmTypeInterventionsDescription
Quadratus Lumborum block groupExperimentalDiagnostic Test: Quadratus Lumborum block; Drug: BupivacaineQuadratus Lumborum block group (QL) patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.125%
Transversus abdominis plane block groupExperimentalDiagnostic Test: Tranversus Abdominis plane block; Drug: BupivacaineTransversus abdominis plane block (TAP) patients will receive a bilateral TAP block using Bupivicaine 0.125%
  • Quadratus Lumborum block (Diagnostic test), also known as QLB: 0.2 ml/kg bupivicaine 0.125% injected bilateraly at the posterior border of the quadratus Lumborum muscle
  • Tranversus Abdominis plane block (Diagnostic test), also known as TAP: 0.2 ml/kg bupivicaine 0.125% injected bilateraly between internal oblique and transversus abdominis muscles.
  • Bupivacaine (Drug): 0.2 ml/kg bupivicaine

+Outcome measures

Primary outcomes

  • Total oxycodone used in the first 24 hours after surgery [24 hours]: Total cumulative oxycodone dose in mg used in the first 24 hours after surgery

Secondary outcomes

  • Severity of postoperative pain via visual analogue pain scale (VAS) [24 hours]: VAS range from 0 for no pain to 10 for worst pain imaginable

+Eligibility

Sex: Male, ages: 18 Years to 90 Years

Inclusion Criteria:

* Pateints who will have prostatectomy ASA II or III

Exclusion Criteria: Patient refusal Local infection at the site of injection Allergy to study medications Sepsis Anatomic abnormalities Systemic anticoagulation or coagulopathy Inability to comprehend or participate in pain scoring system Inability to use intravenous patient controlled analgesia

\-

+Locations (1)

FacilityCityCountryStatus
University Hospital in CracowKrakowPoland

+Investigators

My Notes